AI assistant
Sending…
ImmunityBio, Inc. — Director's Dealing 2018
Mar 27, 2018
31529_dirs_2018-03-26_dddcdabd-c0c7-491d-94f1-75862dfd25d0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NantKwest, Inc. (NK)
CIK: 0001326110
Period of Report: 2018-03-23
Reporting Person: Nelson Sonja (Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-23 | Common Stock | M | 15000 | $0.00 | Acquired | 15000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-23 | Restricted Stock Units | $ | M | 15000 | Disposed | Common Stock (15000) | Direct |
Footnotes
F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 50% of the RSUs vested on March 23, 2018, and the remaining 50% of the RSUs will vest on March 23, 2020.
F2: Each restricted stock unit represents a contingent right to receive one share of NantKwest, Inc. common stock.
More from ImmunityBio, Inc.
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Regulatory Filings
2026
Apr 9
Regulatory Filings
2026
Apr 6
Regulatory Filings
2026
Mar 31
Director's Dealing
2026
Feb 26
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24
Director's Dealing
2026
Feb 24